|
1
|
Ozols RF: Treatment goals in ovarian
cancer. Int J Gynecol Cancer. 15:3–11. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kang Y and Massagué J:
Epithelial-mesenchymal transitions: Twist in development and
metastasis. Cell. 118:277–279. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zeisberg M and Neilson EG: Biomarkers for
epithelial-mesenchymal transitions. J Clin Invest. 119:1429–1437.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Krantz SB, Shields MA, Dangi-Garimella S,
Munshi HG and Bentrem DJ: Contribution of epithelial-to-mesenchymal
transition and cancer stem cells to pancreatic cancer progression.
J Surg Res. 173:105–112. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dalerba P, Cho RW and Clarke MF: Cancer
stem cells: Models and concepts. Annu Rev Med. 58:267–284. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kay R, Rosten PM and Humphries RK: CD24, a
signal transducer modulating B cell activation responses, is a very
short peptide with a glycosyl phosphatidylinositol membrane anchor.
J Immunol. 147:1412–1416. 1991.PubMed/NCBI
|
|
10
|
Aigner S, Ruppert M, Hubbe M, Sammar M,
Sthoeger Z, Butcher EC, Vestweber D, Altevogt P and Kaufmann SHE:
Heat stable antigen (mouse CD24) supports myeloid cell binding to
endothelial and platelet P-selectin. Int Immunol. 7:1557–1565.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lee KM, Ju JH, Jang K, Yang W, Yi JY, Noh
DY and Shin I: CD24 regulates cell proliferation and transforming
growth factor β-induced epithelial to mesenchymal transition
through modulation of integrin β1 stability. Cell Signal.
24:2132–2142. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Aigner S, Sthoeger ZM, Fogel M, Weber E,
Zarn J, Ruppert M, Zeller Y, Vestweber D, Stahel R, Sammar M, et
al: CD24, a mucin-type glycoprotein, is a ligand for P-selectin on
human tumor cells. Blood. 89:3385–3395. 1997.PubMed/NCBI
|
|
13
|
Sammar M, Aigner S and Altevogt P:
Heat-stable antigen (mouse CD24) in the brain: Dual but distinct
interaction with P-selectin and L1. Biochim Biophys Acta.
1337:287–294. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
King JB, von Furstenberg RJ, Smith BJ,
McNaughton KK, Galanko JA and Henning SJ: CD24 can be used to
isolate Lgr5+ putative colonic epithelial stem cells in
mice. Am J Physiol Gastrointest Liver Physiol. 303:G443–G452. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Deng J, Gao G, Wang L, Wang T, Yu J and
Zhao Z: CD24 expression as a marker for predicting clinical outcome
in human gliomas. J Biomed Biotechnol. 2012:5171722012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shi Y, Gong HL, Zhou L, Tian J and Wang Y:
CD24: A novel cancer biomarker in laryngeal squamous cell
carcinoma. ORL J Otorhinolaryngol Relat Spec. 74:78–85. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kristiansen G, Schlüns K, Yongwei Y,
Denkert C, Dietel M and Petersen I: CD24 is an independent
prognostic marker of survival in nonsmall cell lung cancer
patients. Br J Cancer. 88:231–236. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kristiansen G, Winzer KJ, Mayordomo E,
Bellach J, Schlüns K, Denkert C, Dahl E, Pilarsky C, Altevogt P,
Guski H, et al: CD24 expression is a new prognostic marker in
breast cancer. Clin Cancer Res. 9:4906–4913. 2003.PubMed/NCBI
|
|
19
|
Lee HJ, Kim DI, Kwak C, Ku JH and Moon KC:
Expression of CD24 in clear cell renal cell carcinoma and its
prognostic significance. Urology. 72:603–607. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Su N, Peng L, Xia B, Zhao Y, Xu A, Wang J,
Wang X and Jiang B: Lyn is involved in CD24-induced ERK1/2
activation in colorectal cancer. Mol Cancer. 11:432012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu C, Zheng S, Shen H, Xu K, Chen J, Li
H, Xu Y, Xu A, Chen B, Kaku H, et al: Clinical significance of CD24
as a predictor of bladder cancer recurrence. Oncol Lett. 6:96–100.
2013.PubMed/NCBI
|
|
22
|
Zhu J, Zhang G and Lu H: CD24, COX-2, and
p53 in epithelial ovarian cancer and its clinical significance.
Front Biosci (Elite Ed). 4:2745–2751. 2012.PubMed/NCBI
|
|
23
|
Li C, Heidt DG, Dalerba P, Burant CF,
Zhang L, Adsay V, Wicha M, Clarke MF and Simeone DM: Identification
of pancreatic cancer stem cells. Cancer Res. 67:1030–1037. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gao MQ, Choi YP, Kang S, Youn JH and Cho
NH: CD24+ cells from hierarchically organized ovarian
cancer are enriched in cancer stem cells. Oncogene. 29:2672–2680.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kim KH, Choi JS, Kim JM, Choi YL, Shin YK,
Lee HC, Seong IO, Kim BK, Chae SW and Kim SH: Enhanced CD24
expression in endometrial carcinoma and its expression pattern in
normal and hyperplastic endometrium. Histol Histopathol.
24:309–316. 2009.PubMed/NCBI
|
|
26
|
Taylor MA, Parvani JG and Schiemann WP:
The pathophysiology of epithelial-mesenchymal transition induced by
transforming growth factor-beta in normal and malignant mammary
epithelial cells. J Mammary Gland Biol Neoplasia. 15:169–190. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zavadil J and Böttinger EP: TGF-beta and
epithelial-to-mesenchymal transitions. Oncogene. 24:5764–5774.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lee YH, Albig AR, Regner M, Schiemann BJ
and Schiemann WP: Fibulin-5 initiates epithelial-mesenchymal
transition (EMT) and enhances EMT induced by TGF-beta in mammary
epithelial cells via a MMP-dependent mechanism. Carcinogenesis.
29:2243–2251. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Miettinen PJ, Ebner R, Lopez AR and
Derynck R: TGF-beta induced transdifferentiation of mammary
epithelial cells to mesenchymal cells: Involvement of type I
receptors. J Cell Biol. 127:2021–2036. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jiang J, Tang YL and Liang XH: EMT: A new
vision of hypoxia promoting cancer progression. Cancer Biol Ther.
11:714–723. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bao B, Wang Z, Ali S, Kong D, Banerjee S,
Ahmad A, Li Y, Azmi AS, Miele L and Sarkar FH: Over-expression of
FoxM1 leads to epithelial-mesenchymal transition and cancer stem
cell phenotype in pancreatic cancer cells. J Cell Biochem.
112:2296–2306. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan
A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The
epithelial-mesenchymal transition generates cells with properties
of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Reya T, Morrison SJ, Clarke MF and
Weissman IL: Stem cells, cancer, and cancer stem cells. Nature.
414:105–111. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Roszkowski P, Wronkowski Z, Szamborski J
and Romejko M: Evaluation of selected prognostic factors in ovarian
cancer. Eur J Gynaecol Oncol. 14 Suppl:140–145. 1993.PubMed/NCBI
|
|
35
|
Kristiansen G, Denkert C, Schlüns K, Dahl
E, Pilarsky C and Hauptmann S: CD24 is expressed in ovarian cancer
and is a new independent prognostic marker of patient survival. Am
J Pathol. 161:1215–1221. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Surowiak P, Materna V, Kaplenko I,
Spaczynski M, Dietel M, Kristiansen G, Lage H and Zabel M:
Unfavorable prognostic value of CD24 expression in sections from
primary and relapsed ovarian cancer tissue. Int J Gynecol Cancer.
16:515–521. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Grünert S, Jechlinger M and Beug H:
Diverse cellular and molecular mechanisms contribute to epithelial
plasticity and metastasis. Nat Rev Mol Cell Biol. 4:657–665. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Takai M, Terai Y, Kawaguchi H, Ashihara K,
Fujiwara S, Tanaka T, Tsunetoh S, Tanaka Y, Sasaki H, Kanemura M,
et al: The EMT (epithelial-mesenchymal-transition)-related protein
expression indicates the metastatic status and prognosis in
patients with ovarian cancer. J Ovarian Res. 7:762014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hollier BG, Tinnirello AA, Werden SJ,
Evans KW, Taube JH, Sarkar TR, Sphyris N, Shariati M, Kumar SV,
Battula VL, et al: FOXC2 expression links epithelial-mesenchymal
transition and stem cell properties in breast cancer. Cancer Res.
73:1981–1992. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Iwatsuki M, Mimori K, Yokobori T, Ishi H,
Beppu T, Nakamori S, Baba H and Mori M: Epithelial-mesenchymal
transition in cancer development and its clinical significance.
Cancer Sci. 101:293–299. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lee TK, Castilho A, Cheung VC, Tang KH, Ma
S and Ng IO: CD24(+) liver tumor-initiating cells drive
self-renewal and tumor initiation through STAT3-mediated NANOG
regulation. Cell Stem Cell. 9:50–63. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yeung TM, Gandhi SC, Wilding JL, Muschel R
and Bodmer WF: Cancer stem cells from colorectal cancer-derived
cell lines. Proc Natl Acad Sci USA. 107:pp. 3722–3727. 2010;
View Article : Google Scholar : PubMed/NCBI
|
